ERBB2 and breast cancer: Tumor characteristics differed with MamD BC cases more likely HR+/HER2- [64% vs. 36% PtD BC] and the reverse for triple negative breast cancer (TNBC) [39% MamD BC vs 61% PtD BC) (p < .001)].